Health Ministers Recommend Johnson & Johnson Vaccine for Over 60s | Free press


Younger people should also be able to decide on preparation after a doctor’s consultation. So far, relatively few doses have been vaccinated by Johnson & Johnson – that could change now.

Berlin (dpa) – Johnson & Johnson’s corona vaccine will generally be used in Germany for over-60s in the future. But after medical advice, younger people can also choose it.

That is what the federal and state health ministers have decided, the German news agency found. The prioritization for this vaccine expires at the same time in GP practices and company doctors. This will happen from next Monday. Federal Health Minister Jens Spahn (CDU) wanted to explain the procedure in Berlin.

As stated in the resolution of the Conference of Health Ministers, ministers take “the reported cases of cerebral venous thrombosis associated with vaccination with the Johnson & Johnson vaccine” seriously. As with the Astrazeneca vaccine, such serious side effects were very rare.

Against this background, the Standing Vaccination Commission proposed the recommendation to vaccinate the preparation “for people over 60”. As with vaccinations with the Astrazeneca vaccine, vaccination should also be possible for children under 60 after medical education and an individual risk assessment.

The special thing about the Johnson & Johnson vaccine is that, in contrast to the corona vaccines used so far, only one syringe is sufficient for complete protection.

Last week, health ministers decided that corona vaccinations with the Astrazeneca preparation will be possible for everyone in the future if those who want to vaccinate decide with their doctor. The prioritization with a fixed priority list for this vaccine has already been completely canceled.

Of the 34.4 million vaccine doses administered to date, only about 18,000 have come from Johnson & Johnson. Deliveries should now increase. Over the weekend, 7.6 million or 9.1 percent of all German citizens were fully vaccinated. Soon every third person has had at least one first injection: 32.3 percent.

Try it for 30 days for € 20.99

Access to all content on and e-paper. (ends automatically)

Now € 0 instead of € 20.99